Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of dabrafenib in paediatric glioma
2015-004015-20Phase 2Unknown
- Sponsor
- Novartis
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dabrafenib + trametinib in low-grade glioma (LGG) and malignant glioma (2 cohorts), sponsored by Novartis. Primary endpoint: Overall Response Rate (ORR) by central independent assessment (HGG cohort). Status: unknown.
02
Drugs
dabrafenib + trametinib
03
Conditions
low-grade glioma (LGG)malignant glioma
Beyond the preview
Go deeper on 2015-004015-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004015-20.